Saturday 17 October 2026 Export IVA’s income statement to Excel — free account

Inventiva S.A. Sponsored ADR

Inventiva S.A. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million, down 43.7% from fiscal 2024.

2.94 0.17 −5.47%

Follow IVA

Alert me

Market cap: $740.0M
P/E: 0.0×
Fwd P/E: −4.6×
Dividend yield: —
F-score: 4/9
Altman Z: −1.36
Beneish M: −7.91
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 0.00%

Capital & Financial Ratios $m

Market Cap 739.99

Revenue 19.63

Net Income (280.34)

Free Cash Flow (137.54)

Net Debt (115.65)

Current Ratio 3.81

Debt/Equity 1.13

P/E ratio 0.00

Fwd P/E (4.61)

P/S ratio 5.79

P/B ratio 1.66

Past 5Y EPS Growth —

This Y EPS Growth 67.65%

Next Y EPS Growth 0.75%

Next Y revenue growth (35.70%)

Next 5Y EPS Growth 47.99%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 13.26%

10-year low 10-year high

P/B against its own 10 years 0.36%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	29	104	112	193
Receivables	10	6	5	8
Inventory	0	—	—	—
Other	13	10	159	85
	52	121	277	286

	2023	2024	2025	Q'26
Payables	41	36	29	40
ST’ Debt	6	6	37	15
Other	8	89	22	19
	54	131	88	75

Compound Annual Growth %

	10y	5y	3y
Sales	—	8.33%	(23.23%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	0.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	9
’24	—	—	—	—	16
’23	—	—	—	—	25
’22	—	—	—	—	20
’21	0	2	—	—	10
’20	1	0	—	0	6

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	(61)	—	—	(119)
’24	—	(52)	—	—	(93)
’23	—	—	—	—	(88)
’22	—	—	—	—	(47)
’21	(9)	(14)	—	—	(56)
’20	(4)	(8)	—	(29)	(35)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	(61)	—	—	(119)
’24	—	(52)	—	—	(93)
’23	—	0	—	—	(89)
’22	—	0	—	(20)	(48)
’21	(9)	(15)	—	(32)	(57)
’20	(4)	(8)	—	(29)	(35)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(2.15)
’24	—	—	—	—	(3.33)
’23	—	—	—	—	(2.63)
’22	—	—	—	—	(1.38)
’21	(0.28)	(0.45)	—	—	(1.50)
’20	(0.26)	(0.58)	—	(0.58)	(1.13)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	9.01	10.52	3.49	2.22	1.53	2.11	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	15.95	19.06	13.66	6.82	4.75	7.98
People
People	Employees	—	—	—	88	94	105	113	123	118	77
	Revenue/emp, $m	0.00	0.00	0.00	0.14	0.06	0.10	0.18	0.20	0.14	0.12
Income, $m
Income, $m	Revenue	10	6	4	13	6	10	20	25	16	9
	Gross margin, %	0.00	0.00	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(18)	(32)	(44)	(34)	(38)	(58)	(57)	(119)	(199)	(401)
	EBT margin, %	(176.94)	(556.22)	(1,194.90)	(267.63)	(638.78)	(579.59)	(288.58)	(474.11)	(1,248.89)	(4,467.77)
	Net income	(7)	0	(39)	(34)	(38)	(59)	(57)	(120)	(199)	(401)
	Depreciation	2	2	3	2	2	(2)	2	3	6	4
Per share, $
Per share, $	Revenue	0.63	0.37	0.14	0.54	0.18	0.26	0.48	0.55	0.27	0.05
	Earnings	(0.47)	(1.48)	(1.89)	(1.43)	(1.13)	(1.50)	(1.38)	(2.63)	(3.33)	(2.15)
	Cash flow	(1.00)	(1.32)	(1.54)	(1.35)	(1.03)	(1.44)	(1.14)	(1.95)	(1.56)	(0.64)
	Capex	0.00	0.00	0.00	(0.01)	(0.01)	(0.01)	(0.01)	(0.01)	(0.01)	0.00
	Free cash flow	(1.00)	(1.32)	(1.54)	(1.36)	(1.04)	(1.45)	(1.16)	(1.96)	(1.56)	(0.64)
	Book value	2.40	4.81	2.78	1.97	3.75	2.68	1.16	(0.76)	(1.93)	(0.17)
	Shares, m	16	16	25	24	34	39	41	45	60	187
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	44.07	44.07	44.07	70.80	70.85	9.67	9.26	4.22	9.16
	P/B	8.56	8.56	8.56	8.56	4.09	5.28	4.00	0.00	0.00	0.00
	EV/Sales	38.86	38.86	38.86	38.86	55.75	59.20	6.88	9.48	6.54	5.41
	EV/FCF	(5.44)	(5.44)	(5.44)	(5.44)	(6.02)	(5.23)	(1.46)	(1.45)	(1.22)	(0.77)
Cash, $m
Cash, $m	Operating cash flow	(16)	(20)	(39)	(32)	(35)	(56)	(47)	(88)	(93)	(119)
	Capex	0	(1)	(1)	0	0	(1)	(1)	0	0	0
	Free cash flow	(16)	(20)	(39)	(32)	(35)	(57)	(48)	(89)	(93)	(119)
Balance, $m
Balance, $m	Working capital	34	70	65	39	136	110	80	(2)	(10)	189
	Total debt	1	1	0	0	11	12	36	41	59	68
	Net debt	(26)	(71)	(65)	(40)	(109)	(90)	(55)	11	(46)	(45)
	Shareholders’ equity	38	75	71	46	127	105	48	(35)	(115)	(32)
Returns, %
Returns, %	ROA	(10.52)	(89.41)	(53.98)	(43.52)	(34.52)	(38.76)	(42.91)	(121.02)	(195.41)	(194.96)
	ROIC	0.00	0.00	0.00	(334.31)	(119.22)	(262.00)	0.00	0.00	0.00	0.00
	ROE	(13.22)	(40.99)	(53.16)	(57.77)	(44.29)	(50.59)	(74.72)	(1,804.49)	265.66	542.65

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2021 · fundamentals updated 30 Sep 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
DNA Ginkgo Bioworks Holdings, Inc.	$791.9M	— (loss-making)	— (loss-making)	−48.49% (below 0%: shrinking)	n/m	−16.38% (below 0%: shrinking)	91.47%	(290.47%)	Compare
GERN Geron Corporation	$790.2M	— (loss-making)	— (loss-making)	+17.22% (above 0%: growing)	n/m	+41.82% (above 0%: growing)	83.92%	(21.74%)	Compare
SANA Sana Biotechnology, Inc.	$740.9M	— (loss-making)	—	—	n/m	−5.46% (below 0%: shrinking)	0.00%	0.00%	Compare
IVA Inventiva S.A. Sponsored ADR	$740.0M	— (loss-making)	— (loss-making)	−10.77% (below 0%: shrinking)	n/m	−20,989.22% (below 0%: shrinking)	0.00%	0.00%
LXRX Lexicon Pharmaceuticals, Inc.	$734.2M	— (loss-making)	— (loss-making)	−97.60% (below 0%: shrinking)	n/m	−154.09% (below 0%: shrinking)	94.36%	(3,835.26%)	Compare
IMMX Immix Biopharma, Inc.	$719.6M	— (loss-making)	—	—	n/m	−116.22% (below 0%: shrinking)	—	0.00%	Compare
ACHV Achieve Life Sciences, Inc.	$717.2M	— (loss-making)	—	+54.44% (above 0%: growing)	n/m	−19.01% (below 0%: shrinking)	0.00%	0.00%	Compare
FDMT 4D Molecular Therapeutics, Inc.	$711.0M	— (loss-making)	— (loss-making)	+25,106.67% (above 0%: growing)	n/m	−61.28% (below 0%: shrinking)	100.00%	(2,037.16%)	Compare
ANL Adlai Nortye Ltd. Sponsored ADR	$710.1M	—	—	—	—	+46.03% (above 0%: growing)	—	—	Compare
Median of peers	$726.9M	—	—	+17.22%	—	−17.69%	87.69%	(21.74%)

All 614 Biotechnology stocks →

Inventiva S.A. Sponsored ADR (IVA) key facts

Concern: Inventiva S.A. Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $9.0 million, down 43.7% from fiscal 2024.
Inventiva S.A. Sponsored ADR (IVA) is a Biotechnology company in the Healthcare sector, traded in the US as an ADR.
As of October 16, 2026, IVA traded at $2.94, a market capitalization of $740.0 million.
Return on equity was 542.7% and debt-to-equity 1.13.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −1.36 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations · fundamentals updated Sep 30, 2026.